Increased Systolic and Diastolic Blood Pressure is Associated with Altered Gut Microbiota Composition and Butyrate Production in Early Pregnancy

Hypertension

Volumn 68, Issue 4, 2016, Pages 974-981

  Gomez Arango, Luisa F ^a   Barrett, Helen L ^a,d   McIntyre, H David ^b   Callaway, Leonie K ^a,d   Morrison, Mark ^c   Dekker Nitert, Marloes ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Mater Research Institute   (Netherlands)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

blood pressure; butyrate; dysbiosis; hypertension; pregnancy

Indexed keywords

BUTYRIC ACID; PLASMINOGEN ACTIVATOR INHIBITOR 1; RNA 16S; AUTACOID; BUTYRIC ACID DERIVATIVE;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; BODY MASS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; ELEVATED BLOOD PRESSURE; FEMALE; FIRST TRIMESTER PREGNANCY; GENE SEQUENCE; HELLP SYNDROME; HUMAN; INTESTINE FLORA; MAJOR CLINICAL STUDY; MATERNAL HYPERTENSION; OBESITY; PREECLAMPSIA; PREGNANT WOMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; SYSTOLIC BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; COMPARATIVE STUDY; COMPLICATION; DYSBIOSIS; GESTATIONAL AGE; HYPERTENSION, PREGNANCY-INDUCED; METABOLISM; MULTIVARIATE ANALYSIS; NONPARAMETRIC TEST; PATHOPHYSIOLOGY; PATIENT SELECTION; PHYSIOLOGY; PREGNANCY; PREGNANCY OUTCOME; PROCEDURES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

ADULT; BLOOD PRESSURE DETERMINATION; BODY MASS INDEX; BUTYRATES; DYSBIOSIS; FEMALE; GASTROINTESTINAL MICROBIOME; GESTATIONAL AGE; HUMANS; HYPERTENSION, PREGNANCY-INDUCED; INFLAMMATION MEDIATORS; MULTIVARIATE ANALYSIS; OBESITY; OVERWEIGHT; PATIENT SELECTION; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREGNANCY; PREGNANCY OUTCOME; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC;

EID: 84981718815     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.116.07910     Document Type: Article

References (53)

1. Kotsis V, Nilsson P, Grassi G, Mancia G, Redon J, Luft F, Schmieder R, Engeli S, Stabouli S, Antza C, Pall D, Schlaich M, Jordan J; WG on Obesity, Diabetes, the High Risk Patient, European Society of Hypertension. New developments in the pathogenesis of obesityinduced hypertension. J Hypertens. 2015;33:1499-1508. doi: 10.1097/HJH.0000000000000645.
2. Yang T, Santisteban MM, Rodriguez V, Li E, Ahmari N, Carvajal JM, Zadeh M, Gong M, Qi Y, Zubcevic J, Sahay B, Pepine CJ, Raizada MK, Mohamadzadeh M. Gut dysbiosis is linked to hypertension. Hypertension. 2015;65:1331-1340. doi: 10.1161/HYPERTENSIONAHA.115.05315.
3. Howitt MR, Garrett WS. A complex microworld in the gut: gut microbiota and cardiovascular disease connectivity. Nat Med. 2012;18:1188-1189. doi: 10.1038/nm.2895.
4. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature. 2006;444:1022-1023. doi: 10.1038/4441022a.
5. Xu P, Li M, Zhang J, Zhang T. Correlation of intestinal microbiota with overweight and obesity in Kazakh school children. BMC Microbiol. 2012;12:283. doi: 10.1186/1471-2180-12-283.
6. Lyte M. Probiotics function mechanistically as delivery vehicles for neuroactive compounds: microbial endocrinology in the design and use of probiotics. Bioessays. 2011;33:574-581. doi: 10.1002/bies.201100024.
7. El Aidy S, Dinan TG, Cryan JF. Immune modulation of the brain-gut-microbe axis. Front Microbiol. 2014;5:146. doi: 10.3389/fmicb.2014.00146.
8. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56:1761-1772. doi: 10.2337/db06-1491.
9. Mell B, Jala VR, Mathew AV, Byun J, Waghulde H, Zhang Y, Haribabu B, Vijay-Kumar M, Pennathur S, Joe B. Evidence for a link between gut microbiota and hypertension in the Dahl rat. Physiol Genomics. 2015;47:187-197. doi: 10.1152/physiolgenomics.00136.2014.
10. Khalesi S, Sun J, Buys N, Jayasinghe R. Effect of probiotics on blood pressure: a systematic review and meta-analysis of randomized, controlled trials. Hypertension. 2014;64:897-903. doi: 10.1161/HYPERTENSIONAHA.114.03469.
11. Vital M, Howe AC, Tiedje JM. Revealing the bacterial butyrate synthesis pathways by analyzing (meta)genomic data. MBio. 2014;5:e00889. doi: 10.1128/mBio.00889-14.
12. Louis P, Duncan SH, McCrae SI, Millar J, Jackson MS, Flint HJ. Restricted distribution of the butyrate kinase pathway among butyrate-producing bacteria from the human colon. J Bacteriol. 2004;186:2099-2106.
13. Pryde SE, Duncan SH, Hold GL, Stewart CS, Flint HJ. The microbiology of butyrate formation in the human colon. FEMS Microbiol Lett. 2002;217:133-139.
14. Duncan SH, Barcenilla A, Stewart CS, Pryde SE, Flint HJ. Acetate utilization and butyryl coenzyme A (CoA):acetate-CoA transferase in butyrate-producing bacteria from the human large intestine. Appl Environ Microbiol. 2002;68:5186-5190.
15. Smith TJ, Piscatelli JJ, Andersen V, Wang HS, Lance P. n-Butyrate induces plasminogen activator inhibitor type 1 messenger RNA in cultured Hep G2 cells. Hepatology. 1996;23:866-871. doi: 10.1002/hep.510230430.
16. Mortensen FV, Jørgensen B, Christiansen HM, Sloth-Nielsen J, Wolff B, Hessov I. Short-chain fatty acid enemas stimulate plasminogen activator inhibitor-1 after abdominal aortic graft surgery: a double-blinded, placebo-controlled study. Thromb Res. 2000;98:361-366.
17. Martin C, Cameron J, McGrath B. Mechanical and circulating biomarkers in isolated clinic hypertension. Clin Exp Pharmacol Physiol. 2008;35:402-408. doi: 10.1111/j.1440-1681.2008.04886.x.
18. Mertens I, Ballaux D, Funahashi T, Matsuzawa Y, Van der Planken M, Verrijken A, Ruige JB, Van Gaal LF. Inverse relationship between plasminogen activator inhibitor-I activity and adiponectin in overweight and obese women. Interrelationship with visceral adipose tissue, insulin resistance, HDL-chol and inflammation. Thromb Haemost. 2005;94:1190-1195.
19. Chen YS, Shen L, Mai RQ, Wang Y. Levels of microRNA-181b and plasminogen activator inhibitor-1 are associated with hypertensive disorders complicating pregnancy. Exp Ther Med. 2014;8:1523-1527. doi: 10.3892/etm.2014.1946.
20. Sartori MT, Serena A, Saggiorato G, Campei S, Faggian D, Pagnan A, Paternoster DM. Variations in fibrinolytic parameters and inhibin-A in pregnancy: related hypertensive disorders. J Thromb Haemost. 2008;6:352-358. doi: 10.1111/j.1538-7836.2007.02840.x.
21. Reith A, Booth NA, Moore NR, Cruickshank DJ, Bennett B. Plasminogen activator inhibitors (PAI-1 and PAI-2) in normal pregnancies, pre-eclampsia and hydatidiform mole. Br J Obstet Gynaecol. 1993;100:370-374.
22. Estellés A, Gilabert J, Aznar J, Loskutoff DJ, Schleef RR. Changes in the plasma levels of type 1 and type 2 plasminogen activator inhibitors in normal pregnancy and in patients with severe preeclampsia. Blood. 1989;74:1332-1338.
23. Pinheiro MB, Carvalho MG, Martins-Filho OA, Freitas LG, Godoi LC, Alpoim PN, Gomes KB, Dusse LM. Severe preeclampsia: are hemostatic and inflammatory parameters associated? Clin Chim Acta. 2014;427:65-70. doi: 10.1016/j.cca.2013.09.050.
24. Guven S, Sonmez M, Karahan SC. The role of fibrinolytic and antifibrinolytic activities in the pathophysiology of HELLP syndrome. Hypertens Pregnancy. 2011;30:275-286. doi: 10.3109/10641950902968718.
25. Nitert MD, Barrett HL, Foxcroft K, Tremellen A, Wilkinson S, Lingwood B, Tobin JM, McSweeney C, O'Rourke P, McIntyre HD, Callaway LK. SPRING: an RCT study of probiotics in the prevention of gestational diabetes mellitus in overweight and obese women. BMC Pregnancy Childbirth. 2013;13:50. doi: 10.1186/1471-2393-13-50.
26. Lowe SA, Bowyer L, Lust K, McMahon LP, Morton MR, North RA, Paech MJ, Said JM; Society of Obstetric Medicine of Australia and New Zealand. The SOMANZ guidelines for the management of hypertensive disorders of pregnancy 2014. Aust N Z J Obstet Gynaecol. 2015;55:11-16. doi: 10.1111/ajo.12253.
27. Yu Z, Morrison M. Improved extraction of PCR-quality community DNA from digesta and fecal samples. Biotechniques. 2004;36:808-812.
28. Caporaso JG, Kuczynski J, Stombaugh J, et al. QIIME allows analysis of high-throughput community sequencing data. Nat Methods. 2010;7:335-336. doi: 10.1038/nmeth.f.303.
29. Mortensen PB, Holtug K, Bonnén H, Clausen MR. The degradation of amino acids, proteins, and blood to short-chain fatty acids in colon is prevented by lactulose. Gastroenterology. 1990;98:353-360.
30. Pluznick J. A novel scfa receptor, the microbiota, and blood pressure regulation. Gut Microbes. 2014;5:202-207.
31. Li HP, Chen X, Li MQ. Butyrate alleviates metabolic impairments and protects pancreatic ? cell function in pregnant mice with obesity. Int J Clin Exp Pathol. 2013;6:1574-1584.
32. Lin Y, Fang ZF, Che LQ, Xu SY, Wu D, Wu CM, Wu XQ. Use of sodium butyrate as an alternative to dietary fiber: effects on the embryonic development and anti-oxidative capacity of rats. PLoS One. 2014;9:e97838. doi: 10.1371/journal.pone.0097838.
33. Goicoa S, Alvarez S, Ricordi C, Inverardi L, Domínguez-Bendala J. Sodium butyrate activates genes of early pancreatic development in embryonic stem cells. Cloning Stem Cells. 2006;8:140-149. doi: 10.1089/clo.2006.8.140.
34. Das ZC, Gupta MK, Uhm SJ, Lee HT. Increasing histone acetylation of cloned embryos, but not donor cells, by sodium butyrate improves their in vitro development in pigs. Cell Reprogram. 2010;12:95-104. doi: 10.1089/cell.2009.0068.
35. Durgan DJ, Ganesh BP, Cope JL, Ajami NJ, Phillips SC, Petrosino JF, Hollister EB, Bryan RM Jr. Role of the gut microbiome in obstructive sleep apnea-induced hypertension. Hypertension. 2016;67:469-474. doi: 10.1161/HYPERTENSIONAHA.115.06672.
36. Nagai F, Morotomi M, Watanabe Y, Sakon H, Tanaka R. Alistipes indistinctus sp. nov. and Odoribacter laneus sp. nov., common members of the human intestinal microbiota isolated from faeces. Int J Syst Evol Microbiol. 2010;60(pt 6):1296-1302. doi: 10.1099/ijs.0.014571-0.
37. Göker M, Gronow S, Zeytun A, et al. Complete genome sequence of Odoribacter splanchnicus type strain (1651/6). Stand Genomic Sci. 2011;4:200-209. doi: 10.4056/sigs.1714269.
38. Mosele JI, Gosalbes MJ, Macià A, Rubió L, Vázquez-Castellanos JF, Jiménez Hernández N, Moya A, Latorre A, Motilva MJ. Effect of daily intake of pomegranate juice on fecal microbiota and feces metabolites from healthy volunteers. Mol Nutr Food Res. 2015;59:1942-1953. doi: 10.1002/mnfr.201500227.
39. Morgan XC, Tickle TL, Sokol H, Gevers D, Devaney KL, Ward DV, Reyes JA, Shah SA, LeLeiko N, Snapper SB, Bousvaros A, Korzenik J, Sands BE, Xavier RJ, Huttenhower C. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol. 2012;13:R79. doi: 10.1186/gb-2012-13-9-r79.
40. Giménez-Bastida JA, Larrosa M, González-Sarrías A, Tomás-Barberán F, Espín JC, García-Conesa MT. Intestinal ellagitannin metabolites ameliorate cytokine-induced inflammation and associated molecular markers in human colon fibroblasts. J Agric Food Chem. 2012;60:8866-8876. doi: 10.1021/jf300290f.
41. Giménez-Bastida JA, González-Sarrías A, Larrosa M, Tomás-Barberán F, Espín JC, García-Conesa MT. Ellagitannin metabolites, urolithin A glucuronide and its aglycone urolithin A, ameliorate TNF-?-induced inflammation and associated molecular markers in human aortic endothelial cells. Mol Nutr Food Res. 2012;56:784-796. doi: 10.1002/mnfr.201100677.
42. Lyon CJ, Hsueh WA. Effect of plasminogen activator inhibitor-1 in diabetes mellitus and cardiovascular disease. Am J Med. 2003;115(suppl 8A):62S-68S.
43. Correia ML, Haynes WG. A role for plasminogen activator inhibitor-1 in obesity: from pie to PAI? Arterioscler Thromb Vasc Biol. 2006;26:2183-2185. doi: 10.1161/01.ATV.0000244018.24120.70.
44. Ali Nahit Sendur M, Sain Guven G, Yorgun H, Hakan Ates A, Canpolat U, Sunman H, Karahan S, Kaya B. Effect of antihypertensive therapy on endothelial markers in newly diagnosed stage 1 hypertension: a randomized single-centre study. Anatol J Cardiol. 2014;14:363-369.
45. Gavriilaki E, Gkaliagkousi E, Nikolaidou B, Triantafyllou G, Chatzopoulou F, Douma S. Increased thrombotic and impaired fibrinolytic response to acute exercise in patients with essential hypertension: the effect of treatment with an angiotensin II receptor blocker. J Hum Hypertens. 2014;28:606-609. doi: 10.1038/jhh.2014.18.
46. Prochazka M, Procházková J, Lubuŝký M, Pilka R, Úlehlová J, Michalec I, Polák P, Kacerovský M, Slavik L. Markers of endothelial activation in preeclampsia. Clin Lab. 2015;61:39-46.
47. Morgan JA, Bombell S, McGuire W. Association of plasminogen activator inhibitor-type 1 (-675 4G/5G) polymorphism with pre-eclampsia: systematic review. PLoS One. 2013;8:e56907. doi: 10.1371/journal. pone.0056907.
48. Boe AE, Eren M, Murphy SB, Kamide CE, Ichimura A, Terry D, McAnally D, Smith LH, Miyata T, Vaughan DE. Plasminogen activator inhibitor-1 antagonist TM5441 attenuates N?-nitro-L-arginine methyl ester-induced hypertension and vascular senescence. Circulation. 2013;128:2318-2324. doi: 10.1161/CIRCULATIONAHA.113.003192.
49. Queipo-Ortuño MI, Boto-Ordóñez M, Murri M, Gomez-Zumaquero JM, Clemente-Postigo M, Estruch R, Cardona Diaz F, Andrés-Lacueva C, Tinahones FJ. Influence of red wine polyphenols and ethanol on the gut microbiota ecology and biochemical biomarkers. Am J Clin Nutr. 2012;95:1323-1334. doi: 10.3945/ajcn.111.027847.
50. Munukka E, Wiklund P, Pekkala S, Völgyi E, Xu L, Cheng S, Lyytikäinen A, Marjomäki V, Alen M, Vaahtovuo J, Keinänen-Kiukaanniemi S, Cheng S. Women with and without metabolic disorder differ in their gut microbiota composition. Obesity (Silver Spring). 2012;20:1082-1087. doi: 10.1038/oby.2012.8.
51. Jose PA, Raj D. Gut microbiota in hypertension. Curr Opin Nephrol Hypertens. 2015;24:403-409. doi: 10.1097/MNH.0000000000000149.
52. Brantsaeter AL, Myhre R, Haugen M, Myking S, Sengpiel V, Magnus P, Jacobsson B, Meltzer HM. Intake of probiotic food and risk of preeclampsia in primiparous women: the Norwegian Mother and Child Cohort Study. Am J Epidemiol. 2011;174:807-815. doi: 10.1093/aje/kwr168.
53. Lye HS, Kuan CY, Ewe JA, Fung WY, Liong MT. The improvement of hypertension by probiotics: effects on cholesterol, diabetes, renin, and phytoestrogens. Int J Mol Sci. 2009;10:3755-3775. doi: 10.3390/ijms10093755.